ArticleBiological psychiatry2017
Association Between Substance Use Disorder and Polygenic Liability to Schizophrenia.
Article in Biological psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pairwise genetic meta-analyses between schizophrenia and substance dependence phenotypes reveals novel association signals with pharmacological significance.Translational psychiatry · 2022Pooled it
- Polygenic liability for schizophrenia predicts shifting-specific executive function deficits and tobacco use in a moderate drinking community sample.Psychiatry research · 2019Pooled it
- Use of polygenic risk scores of nicotine metabolism in predicting smoking behaviors.Pharmacogenomics · 2018Pooled it
- Shared genetic effects among schizophrenia, substance use disorder, and hippocampal volume in a multiplex extended pedigree sample.Schizophrenia research · 2026Article
- Substance-Induced Psychiatric Disorders, Epigenetic and Microbiome Alterations, and Potential for Therapeutic Interventions.Brain sciences · 2024Review
- Childhood trauma and psychosis-Searching for causes and mechanisms.Schizophrenia research · 2023Article
- The collaborative study on the genetics of alcoholism: Genetics.Genes, brain, and behavior · 2023Review
- Independent contribution of polygenic risk for schizophrenia and cannabis use in predicting psychotic-like experiences in young adulthood: testing gene × environment moderation and mediation.Psychological medicine · 2023Article
- Examining the shared etiology of psychopathology with genome-wide association studies.Physiological reviews · 2023Review
- Risk for alcohol use problems in severe mental illness: Interactions with sex and racial/ethnic minority status.Journal of affective disorders · 2023Article
- Psychosocial Life Aspects among Substance Misuse Clients who are at Rehabilitation Phase: A Narrative Review.Health psychology research · 2023Article
- Regulation of sex differences in risk-based decision making by gonadal hormones: Insights from rodent models.Behavioural processes · 2022Review
- Chromatin architecture in addiction circuitry identifies risk genes and potential biological mechanisms underlying cigarette smoking and alcohol use traits.Molecular psychiatry · 2022Article
- Polygenic risk prediction based on singular value decomposition with applications to alcohol use disorder.BMC bioinformatics · 2022Article
- Using Experience Sampling Methodology Data to Characterize the Substance Use of Youth With or At-Risk of Psychosis.Frontiers in psychiatry · 2022Article
- Molecular genetics of cocaine use disorders in humans.Molecular psychiatry · 2022Review
- Primary Psychosis: Risk and Protective Factors and Early Detection of the Onset.Diagnostics (Basel, Switzerland) · 2021Review
- Genetics of substance use disorders in the era of big data.Nature reviews. Genetics · 2021Review
- Review
- Genome-wide analyses of smoking behaviors in schizophrenia: Findings from the Psychiatric Genomics Consortium.Journal of psychiatric research · 2021Article
Corrections and comments
- Commented on by
Authors and funding
13 authors.
Funding
Abstract
backgroundThere are high levels of comorbidity between schizophrenia and substance use disorder, but little is known about the genetic etiology of this comorbidity.
methodsWe tested the hypothesis that shared genetic liability contributes to the high rates of comorbidity between schizophrenia and substance use disorder. To do this, polygenic risk scores for schizophrenia derived from a large meta-analysis by the Psychiatric Genomics Consortium were computed in three substance use disorder datasets: the Collaborative Genetic Study of Nicotine Dependence (ascertained for tobacco use disorder; n = 918 cases; 988 control subjects), the Collaborative Study on the Genetics of Alcoholism (ascertained for alcohol use disorder; n = 643 cases; 384 control subjects), and the Family Study of Cocaine Dependence (ascertained for cocaine use disorder; n = 210 cases; 317 control subjects). Phenotypes were harmonized across the three datasets and standardized analyses were performed. Genome-wide genotypes were imputed to the 1000 Genomes reference panel.
resultsIn each individual dataset and in the mega-analysis, strong associations were observed between any substance use disorder diagnosis and the polygenic risk score for schizophrenia (mega-analysis pseudo-R
conclusionsThese results suggest that comorbidity between schizophrenia and substance use disorder is partially attributable to shared polygenic liability. This shared liability is most consistent with a general risk for substance use disorder rather than specific risks for individual substance use disorders and adds to increasing evidence of a blurred boundary between schizophrenia and substance use disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.